Proteomics

Dataset Information

0

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A


ABSTRACT: More than one percent of people have epilepsy worldwide. Levetiracetam (LEV) is a successful new-generation antiepileptic drug (AED), and its derivative, brivaracetam (BRV), shows improved efficacy. Synaptic vesicle glycoprotein 2a (SV2A), a putative membrane transporter in the synaptic vesicles (SV), has been identified as a target of LEV and BRV. SV2A also serves as a receptor for botulinum neurotoxin (BoNT), which is the most toxic protein and has paradoxically emerged as a potent reagent for therapeutic and cosmetic applications. Nevertheless, no structural analysis on AEDs and BoNT recognition by full-length SV2A has been available. Here we describe the cryo-electron microscopy structures of the full-length SV2A in complex with the BoNT receptor-binding domain, BoNT/A2 HC, and either LEV or BRV. The large fourth luminal domain of SV2A binds to BoNT/A2 HC through protein-protein and protein-glycan interactions. LEV and BRV occupy the putative substrate-binding site in an outward-open conformation. A propyl group in BRV creates additional contacts with SV2A, explaining its higher binding affinity than that of LEV, which was further supported by label-free spectral shift assay. Numerous LEV derivatives have been developed as AEDs and positron emission tomography (PET) tracers for neuroimaging. Our work provides a structural framework for AEDs and BoNT recognition of SV2A and a blueprint for the rational design of new AEDs and PET tracers.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Takehiro Suzuki  

LAB HEAD: Naoshi Dohmae

PROVIDER: PXD050355 | Pride | 2024-06-23

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
F009008.dat Other
F009008.mgf Mgf
F009008.mzid.gz Mzid
HSV2A_non-reduced.raw Raw
HSV2A_reduced.raw Raw
Items per page:
1 - 5 of 8
altmetric image

Publications

Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.

Yamagata Atsushi A   Ito Kaori K   Suzuki Takehiro T   Dohmae Naoshi N   Terada Tohru T   Shirouzu Mikako M  

Nature communications 20240418 1


More than one percent of people have epilepsy worldwide. Levetiracetam (LEV) is a successful new-generation antiepileptic drug (AED), and its derivative, brivaracetam (BRV), shows improved efficacy. Synaptic vesicle glycoprotein 2a (SV2A), a putative membrane transporter in the synaptic vesicles (SVs), has been identified as a target of LEV and BRV. SV2A also serves as a receptor for botulinum neurotoxin (BoNT), which is the most toxic protein and has paradoxically emerged as a potent reagent fo  ...[more]

Similar Datasets

2017-08-17 | GSE98655 | GEO
2011-11-10 | E-GEOD-33600 | biostudies-arrayexpress
2019-03-26 | PXD012515 | Pride
2018-06-23 | GSE115865 | GEO
2012-07-19 | E-GEOD-39495 | biostudies-arrayexpress
2024-01-24 | GSE230912 | GEO
2008-01-15 | GSE9997 | GEO
| 2013768 | ecrin-mdr-crc
2011-11-10 | GSE33600 | GEO
| PRJNA859128 | ENA